App 4D and Report for Half-Year Ended 30 June 2021
Filed with ASX ·
6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Telix and Merck pan-cancer clinical collaboration
- TLX66 in Phase II Academic Study of Pediatric Leukemia
- Telix Seneffe Production Facility - Progress Update
- App 4C and Activities Report for June 2021 Quarter
- ZIRCON Phase 3 Renal Cancer Imaging Study - Progress Update
Later from Telix Pharmaceuticals
- Results Presentation and Shareholder Update 1H 2021
- Telix and Radius sign Distribution Agreement for Italy
- FDA Approves Phase II Kidney Cancer Therapy Study
- FDA Extends New Drug Application Review Period for Illuccix
- $12.1M R&D Tax Refund, Overseas Finding Increased to $139M
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals